Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TAK-754
- Development stage
- Phase 2
- Lead developer
- Takeda
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
TAK-754 (also known as BAX 888 and SHP654) is an investigational gene therapy developed for the treatment of hemophilia A. It utilizes an adeno-associated virus serotype 8 (AAV8) vector to deliver a codon-optimized, B-domain deleted factor VIII (FVIII) transgene specifically to the liver. The goal is for patients' livers to produce functional FVIII protein endogenously, thereby reducing or eliminating the need for exogenous FVIII infusions. The transgene cassette has been optimized by reducing CpG motifs to minimize immunogenicity and enhance durability of expression. Clinical trials have focused on safety, dose determination, and efficacy in adult males with severe hemophilia A[1][3][4][5][6].
- Other names
- FVIII gene therapy
02
Targets
F8 (Coagulation Factor VIIIa)
Beyond the preview
Go deeper on TAK-754.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TAK-754.